Overview

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Research purpose: Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination chemotherapy regimens including cisplatin two medicine first-line treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety.
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Treatments:
Cisplatin
Endostar protein
Paclitaxel